180 Life Sciences Teams Up With Hadassah Hospital To Test A New Formulation Of CBD For Enhanced Oral Uptake
Portfolio Pulse from Vuk Zdinjak
180 Life Sciences Corp. (NASDAQ:ATNF) has partnered with professors from the Hebrew University and Hadassah Hospital to conduct a pharmacokinetic study on the uptake of CBD in a new oral formulation. The study aims to address the issue of low and unpredictable uptake of CBD when delivered orally. The new formulation, developed by the team, has shown promising results in preliminary testing on rats. The human study will be conducted at Hadassah Hospital. 180 Life Sciences shares were trading 12.07% higher at $0.919 per share.
August 07, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
180 Life Sciences is partnering with Hebrew University and Hadassah Hospital to test a new oral formulation of CBD. This partnership and the potential of the new formulation have led to a 12.07% increase in the company's stock price.
The partnership with renowned institutions and the potential of the new CBD formulation are likely to boost investor confidence in 180 Life Sciences. This is reflected in the 12.07% increase in the company's stock price. If the human study yields positive results, it could further enhance the company's market position and stock value.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100